Duality Biotherapeutics Updates IPO Filing with HKSE under Chapter 18A Rules
China-based Duality Biotherapeutics, Inc. updated its initial public offering (IPO) filing to the Hong Kong...
CARsgen’s CT041 Awarded Breakthrough Therapy Designation for Gastric Cancer
CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that its chimeric antigen receptor (CAR) T-cell therapy,...
Huge Dental Files for Hong Kong IPO with Diverse Dental Product Portfolio
Shandong-based dental materials company Huge Dental Limited has made an initial public offering (IPO) filing...
CSPC Pharmaceutical’s Sirolimus Receives BTD for Malignant PEComa Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received Breakthrough Therapy Designation...
Pulnovo Medical Raises USD 100M in Series C Financing for Global Expansion
Wuxi-based Pulnovo Medical Limited, a developer of medical devices for pulmonary hypertension and heart failure,...
Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in...
AI in Healthcare: Accelerating Applications in Diagnostics and Multi-omics Analysis
The breakthrough technology of DeepSeek has significantly accelerated the application of AI in the medical...
Biointron Biologics Files for Public Offering, Aims for BSE Listing
On February 11, Biointron Biologics released its tutoring filing report for the public offering of...
Biocytogen Completes DeepSeek Localization, Integrates with “Thousand Mice, Ten Thousand Antibodies” Plan
On February 28, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has completed...
BeiGene’s Q4 and 2024 Financials Highlight Significant Growth and Product Success
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released financial results and corporate updates from...
Zai Lab Q2 and Full-Year 2024 Report Shows Sales Growth and Loss Reduction
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 and full-year 2024...
Viatris Q4 and Full-Year Results Show Greater China Growth
US generics giant Viatris (NASDAQ: VTRS) released its Q4 and full-year 2024 financial results. In...
SciClone Pharmaceuticals Licenses Eisai’s Tasurgratinib for China
China-based SciClone Pharmaceuticals Inc. announced a licensing agreement with Eisai Co., Ltd (TYO: 4523), securing...
Fosun Pharmaceutical’s XS-03 Gets NMPA Green Light for CRC Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...
Sino Biopharmaceutical and Sciwind Biosciences Partner on CPX102 Development
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced a strategic partnership with compatriot firm Sciwind Biosciences...
Bayer’s BlueRock Therapeutics Gets Fast Track for OpCT-001 Therapy
German pharmaceutical giant Bayer (ETR: BAYN) and its wholly owned subsidiary BlueRock Therapeutics LP announced...
Chipscreen Biosciences’ CS12088 Gets NMPA Clearance for Hepatitis B Study
China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that the National Medical Products Administration...
Hengrui Pharmaceuticals Gets NMPA Green Light for SHR-A2009 Study
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that the National Medical Products Administration...
GE Healthcare’s China CEO Yihao Zhang to Retire, Will Song Named Successor
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced the...
Zhongsheng Pharmaceutical’s RAY1225 Gets Green Light for Phase III Study
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval in...